Autoantibodies against Autonomic Nerve Receptors in Adolescent Japanese Girls after Immunization with Human Papillomavirus Vaccine

Akiyo Hineno1,2, Shu-ichi Ikeda1*, Carmen Scheibenbogen3,4, Harald Heidecke2, Kai Schulze-Forster3, Juliane Junker5, Gabriela Riemekasten5, Ralf Dechend6, Duska Dragun7 and Yehuda Shoenfeld8,9

1Intractable Disease Care Center, Shinshu University Hospital, Japan
2Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan
3Department of Medicine, Institute for Medical Immunology, Germany
4Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Germany
5Cell Trend GmbH, Germany
6Department of Rheumatology, Universitätsklinikum Schleswig-Holstein, Germany
7Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, Germany
8Department of Cardiology and Nephrology, HELIOS-Klinikum, Germany
9Department of Nephrology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Germany
10Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Israel

Abstract

In Japan a significant number of adolescent girls complain of unusual symptoms after human papillomavirus (HPV) vaccination, and these symptoms, composed of orthostatic dysregulation, chronic regional pain syndrome (CRPS) and cognitive dysfunction are considered adverse effects of HPV vaccination. However, a causal link between HPV vaccination and these adverse effects has not been demonstrated. In the present study, we investigated autoantibodies against diverse G-protein coupled receptors in the serum of girls who complained of possible adverse effects after HPV vaccination. Fifty five girls with HPV vaccination and 57 girls without HPV immunization were enrolled in the study. The serum levels of autoantibodies against the adrenergic receptors α1, α2, β1 and β2, muscarinic acetylcholine receptors 1, 2, 3, 4, 5; and endothelin receptor A was significantly elevated in girls with HPV vaccination, compared with those in the controls. The serum levels of these autoantibodies tended to decrease with the time course of the illness, but there was no statistically meaningful association between the clinical symptoms and elevated serum levels of these autoantibodies. This preliminary study provides evidence that post-vaccination abnormal autoimmunity plays an important role in the development of unique symptoms after HPV vaccination.

Keywords: Autonomic nerve dysfunction; Autoantibody; Autoimmune disorder; Chronic regional pain syndrome; HPV; Human papillomavirus; Chronic regional pain syndrome

Introduction

Human papillomavirus (HPV) infection promotes uterine and cervical cancers [1], and thus, in 2010, HPV vaccines were introduced worldwide [2,3]. Since then case series of suspected adverse effects after HPV vaccination have been reported from several countries and the symptoms described by independent researchers are similar [4-9].

Previously, we described the clinical characteristics of 40 Japanese girls with possible HPV vaccine-related adverse effects in 2014 [10], and the common symptoms were chronic headache, general fatigue, limb pain and weakness. All these symptoms can be attributed to a combination of orthostatic dysregulation and chronic regional pain syndrome (CRPS); additionally, peripheral sympathetic nerve dysfunction was surmised to be responsible for the occurrence of both orthostatic dysregulation and CRPS [11]. Cognitive dysfunction has also been reported as a possible adverse effect, manifesting late after HPV vaccination: it appears mainly as memory impairment, decreased calculation ability, and transient prosopagnosia-like symptoms, and
calculation ability, and transient prosopagnosia-like symptoms, and therefore, affected patients experienced difficulties in performing their schoolwork, with some being absent from school for long periods [12,13,14]. It has been supposed that long-term orthostatic dysregulation and CRPS might secondarily induce myalgic encephalomyelitis/chronic fatigue syndrome in affected patients [11].

The temporal relationship between HPV vaccination and the occurrence of these unique symptoms strongly suggests a causal link of both events [12], but the exact pathogenesis of orthostatic dysregulation and CRPS after HPV vaccination remains unclear. Recent evidence has shown that autoantibodies against adrenergic and cholinergic receptor play an important role in the development of both orthostatic dysregulation [15, 16] and CRPS [17,18]. Thus, we investigated autoantibodies against diverse G-protein coupled receptors (GPCRs) including adrenergic and muscarinic acetylcholine receptors in the serum of girls who complained possible adverse effects after HPV vaccination and the results were compared with those obtained from non-vaccinated girls.

**Materials and Methods**

**Subjects and human blood samples**

From June 2013 to September 2016, 55 girls were hospitalized in our institute, complaining of several symptoms after HPV vaccination, including 44 patients with a history of vaccination with Cervarix®, 10 with Gardasil®, and one with unknown. Using self-reported answers to printed questionnaires from out institute and medical records from other institutes where available, we obtained a detailed history of the patients’ symptoms to determine the duration between vaccination and the development of the first symptom suspected to be related to the vaccination. All patients underwent complete physical and neurological examinations. If a patient exhibited hypotension or coldness of the limbs, or both, Schellong test and/or digital plethysmography were performed. The latter was recorded in the right second finger and right first toe, while checking the patient’s skin temperature [10]. The controls were age-matched 57 healthy girls, from Nagano prefecture and Kanto area including Tokyo, without a history of immunization with HPV vaccine. Serum was collected from each of the girls after obtaining informed consent.

**Ethics approval**

The study protocol was approved by the Institutional Review Board (approval nos. 4128 & 4150) of Shinshu University School of Medicine, Matsumoto, Japan.

**Quantification of autoantibodies by enzyme-linked immunosorbent assay (ELISA)**

GPCRs-related receptors including adrenergic receptors α1,2 and β1,2; muscarinic acetylcholine receptors M1,2,3,4,5; angiotensin receptor 1 (AT1R) and endothelin receptor (ETAR) were targeted, and the methods to measure these autoantibodies have been previously described [19]. Briefly, the serum level of these autoantibodies was assessed using commercially available solid-phase sandwich ELISA kits according to the manufacturer’s instructions (CellTrend GmbH, Luckewalde, Germany). The concentrations of autoantibodies were calculated as arbitrary units (U) by extrapolation from a standard curve of five standards of concentrations ranging from 2.5 to 120 U/ml. The ELISAs were validated according to the Food and Drug Administration’s Guidance for industry: Bioanalytical Method Validation. Samples from patients and controls were analyzed in the same assay plate, and these samples were analyzed blinded to group allocation.

**Statistical analysis**

Statistical data analyses were performed using the software’s (GraphPad PRISM and BellCurve for Excel). Nonparametric statistical methods were used. Continuous variables were expressed as median and Interquartile Range (IQR). Univariate comparisons of two independent groups were performed using the Mann-Whitney U-test. The results with a two-tailed p-value of <0.05 were considered statistically significant. Contingency analysis was performed by...
Fisher’s exact test. Comparisons between two dependent groups were performed using Wilcoxon matched-pairs signed-rank test. Correlation analysis was performed using nonparametric Spearman coefficient r.

**Results**

**Clinical characteristics of vaccinated girls**

The average age of the 55 vaccinated girls at an initial vaccination was 13.9 ± 2.7 years, and that at symptoms’ onset and blood sampling was 14.7 ± 2.8 years and 16.6 ± 3.1 years, respectively. The time to blood sampling from the first vaccination ranged from 2 to 64 months and the time to blood sampling from the onset of symptoms ranged from 0 to 59 months.

Clinical summary of the 55 girls is presented in Table 1. Symptoms or signs frequently observed in these girls were prolonged general fatigue, chronic headache, widespread pain, limb shaking, dysautonomic symptoms, motor dysfunction, abnormal sensation, sleep disturbance, learning impairment, and menstrual abnormality.

The average age at blood sampling of the 57 controls was 18.8 ± 2.7 years; the controls did not have any serious disorders.

**Serum levels of GPCRs-related autoantibodies**

The serum levels of antibodies against diverse GPCRs tested in the vaccinated girls and controls are shown in Figure 1. Significantly higher autoantibody levels against α1-adrenergic, α2-adrenergic, β1-adrenergic, β2-adrenergic, muscarinic 1 acetylcholine, muscarinic 2 acetylcholine, muscarinic 3 acetylcholine, muscarinic 4 acetylcholine, muscarinic 5 acetylcholine receptors, and ETAR were observed in the vaccinated girls than in the controls (Table 2). However, there was no significant difference in the serum levels of antibodies against AT1R between the vaccinated girls and controls.

**Clinical manifestations, clinical course, and serum levels of autoantibodies**

We compared the symptoms and serum levels of autoantibodies among the vaccinated girls; there was no significant association between the symptoms and serum levels of autoantibodies tested. A comparison of the duration after symptom and serum levels of autoantibodies showed the patients with symptoms for a short duration tended to have high serum levels of autoantibodies, whereas the patients with symptoms for a long duration tended to have low serum levels of autoantibodies (Figure 2). This tendency was more apparent in the serum level change of anti-β1-adrenergic receptor and anti-β2-adrenergic receptor antibodies, muscarinic 2 acetylcholine receptor, muscarinic 3 acetylcholine receptor and muscarinic 5 acetylcholine receptor antibodies (Figure 2c, 2g, 2f and 2i).

**Discussion**

Significant numbers of girls developed a unique disorder after HPV vaccination worldwide; a comparative study of the symptomatic complex has shown that all manifestations were similar between affected Japanese and Danish young females after HPV vaccination [20]. This disorder can be explainable by a combination of orthostatic dysregulation, CRPS and brain cognitive dysfunction [11,21]. Furthermore, these three disorders seem to be causally related.

Autoimmunity and autoantibodies in orthostatic dysregulation, CRPS and chronic fatigue syndrome/myalgic encephalomyelitis

Recently, it has been shown that autoimmunity and
autoantibodies play an important role in a subset of patients with orthostatic dysregulation including postural orthostatic tachycardia syndrome (POTS) and CRPS [18,19]; orthostatic dysregulation is commonly associated with autonomic nerve dysfunctions, in which abnormal bowel movement with vague abdominal pain and bladder dysfunction are frequently observed [23]. Furthermore, POTS is intractable and usually manifests as several non-specific symptoms including migraine-like headache, chest pain, gastroparesis, chronic fatigue [24], and mental confusion (brain-fog) [16]. Autoantibodies against adrenergic receptors β1 and β2, and muscarinic acetylcholine receptors 2 and 3 have been detected in the serum of patients with orthostatic dysregulation [15]. Additionally an antibody toward α1 adrenergic receptor has been also detected in the serum of patients with POTS [16].

CRPS is clinically composed of pain, hyperalgesia, vasomotor and trophic changes in the affected limbs [25] and the appearance of these symptoms are influenced by dysfunctions of peripheral or central sympathetic nervous system [26]. Moreover, cortical reorganization processes are observed in the chronic stage of the patients [27]. CRPS is also considered to be an immune system-mediated disorder and it has been shown that autoantibodies against the adrenergic receptors α1 and α2, and muscarinic acetylcholine receptor 2 are associated with this condition [28]. In practice, immune system-modulating therapies including the administration of corticosteroids, intravenous immunoglobulin (IVIg), and rituximab, and plasma exchange seem to be effective for limb pain and other systemic symptoms in patients with CRPS [28,29].

All these findings suggest that some individuals, not all, might develop orthostatic dysregulation including POTS and CRPS on the basis of abnormal immune responses [28]. Furthermore, long-lasting fatigue and/or pain in patients with each disorder leads to chronic fatigue syndrome/myalgic encephalomyelitis (CSF) [11], and it has been reported that autoantibodies against the adrenergic receptor β2 and muscarinic acetylcholine receptor 3 and 4 were significantly elevated in the serum of patients with CSF [30]. It is, therefore, likely that orthostatic dysregulation, CRPS and CSF belong to the same clinical spectrum and that in a subset of patients these three disorders might be caused by some common autoimmune mechanisms, resulting in a variety of clinical manifestations [11].

### Relationship between clinical symptomatology and autoantibodies in patients after HPV vaccination

In the present study, compared with those in controls, the serum levels of autoantibodies against adrenergic receptors α1, α2, β1, β2; muscarinic acetylcholine receptor 1, 2, 3, 4, and 5; and ETAR were significantly elevated in patients with HPV vaccination. In contrast, there was no significant difference of serum levels of autoantibody against ATIR between both groups of individuals examined. The anti-ATIR and anti-ETAR antibodies are different from the autonomic nerve receptor related autoantibodies, and these two autoantibodies are known to be important biomarkers in transplantation [28].

We further evaluated the correlation between elevated levels of autoantibodies and various clinical manifestations. There was no significant association between the major symptoms including dysautonomic symptoms and serum levels of autoantibodies; in the present study the time of blood sampling after the first vaccination or after the onset of illness considerably varied among the patients examined. The time difference for the former was approximately 3 years and that for the latter was approximately 2 years on an average, indicating that very limited number of patients provided serum samples at the peak of clinical symptoms. Thus, it might be difficult to validate that some symptoms were statistically related to elevated serum levels of autoantibodies. On the contrary, it has been shown that the serum levels of autonomic nerve receptor related autoantibodies were high in the patients at the early stage of illness, and they probably tended to decrease with the time courses of illness, although we did not check the serial serum levels of these autoantibodies in the patients. Therefore, we considered that high serum levels of autonomic nerve receptor-related autoantibodies in the patients were up regulated by HPV vaccination.

The relationship between HPV vaccination and positive serum autoantibodies against autonomic nerve receptors were already described in the previous three case reports [31,32,33]; autoantibodies against adrenergic receptors β1, β2 and muscarinic acetylcholine receptors 2, 3, and 4 were associated with the development of a post-HPV vaccination disorder.

It is well known that autonomic nerve dysfunction including POTS and CRPS do develop in young girls without prior vaccination [34]. Recently, it has been reported that a significant number of non-vaccinated Japanese girls suffer from similar symptoms described as adverse effects after HPV vaccination [35]. In the present study, we found that healthy controls without HPV vaccination have some amount of autoantibodies against the adrenergic receptors α and β, and muscarinic acetylcholine receptors in the serum. It is not

### Table 2: Comparison of area under the curve (AUC), cut off with specificity and sensitivity between girls with/without human papillomavirus vaccine immunization.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>No of girls with HPV immune</th>
<th>No of girls without HPV immune</th>
<th>Cut off (Units/ml)</th>
<th>AUC (%)</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>α1-adr-R-Ab</td>
<td>55</td>
<td>57</td>
<td>4.3</td>
<td>61.5</td>
<td>92.7</td>
<td>40.4</td>
</tr>
<tr>
<td>α2-adr-R-Ab</td>
<td>55</td>
<td>57</td>
<td>17</td>
<td>63.5</td>
<td>67.3</td>
<td>64.9</td>
</tr>
<tr>
<td>β1-adr-R-Ab</td>
<td>55</td>
<td>57</td>
<td>8.1</td>
<td>70.3</td>
<td>65.5</td>
<td>66.7</td>
</tr>
<tr>
<td>β2-adr-R-Ab</td>
<td>55</td>
<td>57</td>
<td>8.2</td>
<td>61.1</td>
<td>56.4</td>
<td>52.6</td>
</tr>
<tr>
<td>M1R-Ab</td>
<td>55</td>
<td>57</td>
<td>4.7</td>
<td>64.6</td>
<td>67.3</td>
<td>59.7</td>
</tr>
<tr>
<td>M2R-Ab</td>
<td>55</td>
<td>57</td>
<td>5.4</td>
<td>78.3</td>
<td>81.8</td>
<td>68.4</td>
</tr>
<tr>
<td>M3R-Ab</td>
<td>55</td>
<td>57</td>
<td>7.1</td>
<td>75.7</td>
<td>83.6</td>
<td>66.7</td>
</tr>
<tr>
<td>M4R-Ab</td>
<td>55</td>
<td>57</td>
<td>17.5</td>
<td>77</td>
<td>80</td>
<td>70.2</td>
</tr>
<tr>
<td>M5R-Ab</td>
<td>55</td>
<td>57</td>
<td>8.1</td>
<td>76.4</td>
<td>72.7</td>
<td>71.9</td>
</tr>
<tr>
<td>AT1R-Ab</td>
<td>55</td>
<td>57</td>
<td>9.1</td>
<td>60.4</td>
<td>92.7</td>
<td>36.8</td>
</tr>
<tr>
<td>ETAR-Ab</td>
<td>55</td>
<td>57</td>
<td>8</td>
<td>61.7</td>
<td>94.6</td>
<td>31.6</td>
</tr>
</tbody>
</table>
clear whether or not there are some functional or conformational difference among these autoantibodies between healthy individuals and patients [36,37], but it is conceivable that low serum levels of these autoantibodies against autonomic nerve receptors can result in the occurrence of orthostatic dysregulation and/or CRPS in non-vaccinated individuals.

Pathogenesis in the induction of autoantibodies after HPV vaccination

A viral/bacterial infection and vaccination can occasionally trigger the development of POTS, CRPS and CFS [22]. Vaccination results in the iatrogenic production of useful antibodies in the human body, but it cannot be ruled out that the exposure to an external stimulus including adjuvants induces unexpected abnormal immune responses, such as a newly evoked situation with an autoimmune abnormality [38].

Regarding HPV vaccine, the primary sequence of the HPV major capsid L1s antigen, which is expressed in HPV strain 6, 11, 16 and 18, is similar to that of several human autonomic nerve receptors and their related proteins, including adrenergic receptors α1 and β1, β adrenergic receptor kinases 1 and 2 [39,40]. According to the publicly available epitope database (The Immune Epitope Data Base), these pentapeptides share their sequence with diverse autonomic nerve receptors and are surmised to be endowed with immunogenicity and antigenicity [41]. It has also been reported that patients produced autoantibodies against more than one autonomic nerve receptor. This is reasonably acceptable by the fact that there is a 40% to 70% sequence homology within the two β adrenergic receptors and within the five muscarinic acetylcholine receptors [30].

Our study had some limitations. First, the number of the study subjects was small. Second, blood sampling in some patients to evaluate serum autoantibodies was not carried out in time.

Conclusion

The exact pathogenesis of various symptoms after HPV vaccination remains unclear and therefore, affected individuals are diagnosed to have psychiatric illness. The symptoms developed after HPV vaccination cannot be clearly categorized into any traditional well-defined conditions. This might be because that a vulnerable subset of the population is at a risk of developing post-HPV vaccination symptoms. To clarify the associated molecular backgrounds, a wide range of approaches are required. The present preliminary study provides that some of the symptoms after HPV vaccination can be attributed to the abnormal autoimmune response after HPV vaccination. Therefore, immune modulatory therapies, which remove these pathologic autoantibodies and/or suppress their production in serum, can be used for the patients with post-HPV vaccination symptoms.

Acknowledgment

We thank Mrs. Misuzu Kurashina for her many helps in this study.

Funding

This study was supported by a grant from a Health and Labour Science Research Grant on Emerging and Re-emerging Infectious Diseases (Establishment of Treatments and Providing Information on Symptoms after HPV vaccination, H28-001) to S.I from the Ministry of Public Health, Labour and Welfare, Japan. This study was also supported by grant from Shinshu Intractable Research Foundation, and Research Grant from Okayama Municipal Hospital to A.H.

References


